STAT+: After a cancer vaccine’s first success, the race is on to expand the impact

A trial from Merck and Moderna presented at the ESMO meeting showed that the personalized mRNA vaccine intismeran combined with Keytruda reduced the risk of recurrence or death in melanoma compared with Keytruda alone. Experts say the approach could in principle extend to other tumor types, marking a breakthrough for the cancer vaccine field.